That is part of the ICE trust transaction. I think, again the major difference, the thing that has happened here in my mind, is that the banks and Creditex and the other inter-broker dealers were working around TCC, to build an inter-dealer solution that looked a lot like swaps clear in Europe. Swaps clear, as you know, is sort of a clearing house within a clearing house at London Clearing House, that handles dealers' interest rate swap positions and it has been very effective and it worked very, very well during the Lehman collapse, frankly, but it was a dealer-only solution and you think a pivotal thing happened at the time of the collapse of Lehman Brothers, which was for the first time the market, both the buy side and the sell side and the regulators, recognized that it was possible for a major dealer to collapse, and it has caused a lot of problems in the OTC space. And so as a result of that, very senior people at these nine banks, listening to our pitch, frankly, concluded that it was time to actually put this OTC business into an open clearing house, of the type that you are used to seeing operating at ICE, where anyone can become a member, and where even people who are not members can get the benefit of clearing. And so that is really what ICE US Trust has been set up to do and so it is a nuance difference, but it is an important difference in a post-Lehman world and as you know, ICE is a public company, has a completely independent Board of Directors, it operates our systems both execution and clearing on behalf of an industry, and it is that focus that we will now have in working on the OTC derivative space.
Howard Chen – Credit Suisse: Thanks. Those distinctions are really helpful. Thanks a lot.